Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trCAR27-28.3Z NK cells
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
trCAR27-28.3Z NK cells are an experimental chimeric antigen receptor (CAR) natural killer (NK) cell therapy designed to target CD70-expressing malignancies. Developed by researchers at MD Anderson Cancer Center, the construct features a truncated CD27 receptor (the natural ligand for CD70) as the antigen-binding domain, fused to CD28 costimulatory and CD3-zeta (3Z) signaling domains. CD70 is a pan-cancer antigen expressed in various hematologic cancers like acute myeloid leukemia (AML) and lymphoma, as well as solid tumors such as renal cell carcinoma, lung cancer, and melanoma, while remaining largely absent from normal tissues. This CAR-NK approach leverages the intrinsic anti-tumor properties of NK cells and their potential for allogeneic use with minimal risk of graft-versus-host disease (GvHD).
- Other names
- CD70-targeted CAR-NK cellsCD-70-targeted CAR-NK cellsCD 70-targeted CAR-NK cellstrCD27-28.3Z CAR-NK cellstrCD-27-28.3Z CAR-NK cellstrCD 27-28.3Z CAR-NK cells
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on trCAR27-28.3Z NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trCAR27-28.3Z NK cells.